Aptevo Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 5, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 5, 2024

APVO$1.13-8.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	December 31, 2023	December 31, 2022
ASSETS
Current assets:
Cash and cash equivalents	$16,904	$22,635
Royalty and milestone receivable	—	2,500
Prepaid expenses	1,473	1,571
Other current assets	689	744
Total current assets	19,066	27,450
Property and equipment, net	895	1,462
Operating lease right-of-use asset	4,881	5,303
Total assets	$24,842	$34,215
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and other accrued liabilities	$3,984	$3,499
Accrued compensation	2,098	2,105
Current portion of long-term debt	—	2,000
Other current liabilities	1,142	1,102
Total current liabilities	7,224	8,706
Long-term debt	—	1,456
Operating lease liability	5,397	6,079
Total liabilities	12,621	16,241
Stockholders' equity:
Preferred stock: $0.001 par value; 15,000,000 shares authorized, zero shares issued or outstanding	—	—
Common stock: $0.001 par value; 500,000,000 shares authorized; 19,468,180 and 6,466,294 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	61	48
Additional paid-in capital	235,607	223,962
Accumulated deficit	(223,447)	(206,036)
Total stockholders' equity	12,221	17,974
Total liabilities and stockholders' equity	$24,842	$34,215

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.